F98 (ATCC® CRL-2397)

Organism: Rattus norvegicus, rat  /  Cell Type: Glioblastoma  /  Tissue: brain  /  Disease: undifferentiated malignant glioma

Organism Rattus norvegicus, rat
Tissue
brain
Cell Type Glioblastoma
Product Format frozen
Morphology glial
Culture Properties adherent
Biosafety Level 1
Disease undifferentiated malignant glioma
Age fetus, 20 days gestation
Applications
The biological characteristics of this tumor closely resemble those of human glioblastoma.
The F98 and RG2 (ATCC CRL-2433) gliomas can be used as rat brain tumor models in experimental neuro-oncology.
This cell line may be used for both in vitro and in vivo studies of a rat brain tumor.
Storage Conditions liquid nitrogen vapor phase
Derivation
This tumor was produced by Drs. A. Koestner and W. Wechsler at The Ohio State University in 1971.
A pregnant CD Fischer rat on day 20 of gestation was inoculated with a single dose of N-ethyl-N-nitrosourea (ENU) (50 mg/kg b.w.). Tumors were harvested and cloned.
Clinical Data
F98 was submitted to the American Type Culture Collection in June, 1998 at passage 2 from a culture established from a subcutaneous tumor grown in a male Fischer rat.
Tumorigenic Yes
Effects
Yes, as an intracerebral xenograft in cats.
Yes, in CD Fischer rats
Comments
The transplantable tumor displays an infiltrative pattern of growth within the brain.
It is weakly immunogenic in syngeneic rats and an intracerebral inoculum of as few as 100 cells are lethal.
Complete Growth Medium The base medium for this cell line is ATCC-formulated Dulbecco's Modified Eagle's Medium, Catalog No. 30-2002. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Subculturing
Protocol:
  1. Remove and discard culture medium.
  2. Briefly rinse the cell layer with 0.05% (w/v) Trypsin- 0.53 mM EDTA solution to remove all traces of serum that contains trypsin inhibitor.
  3. Add 2.0 to 3.0 mL of Trypsin-EDTA solution to flask and observe cells under an inverted microscope until cell layer is dispersed (usually within 5 to 15 minutes).
    Note: To avoid clumping do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach. Cells that are difficult to detach may be placed at 37°C to facilitate dispersal.
  4. Add 6.0 to 8.0 mL of complete growth medium and aspirate cells by gently pipetting.
  5. Add appropriate aliquots of the cell suspension to new culture vessels.
  6. Incubate cultures at 37°C.
Subcultivation Ratio: A subcultivation ratio of 1:6 to 1:10 is recommended
Medium Renewal: Every 2 to 3 days
Cryopreservation
Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO
Storage temperature: liquid nitrogen vapor phase
Culture Conditions
Temperature: 37.0°C
Name of Depositor RF Barth
Passage History
F98 was submitted to the American Type Culture Collection in June, 1998 at passage 2 from a culture established from a subcutaneous tumor grown in a male Fischer rat.
Year of Origin 1971
References

Ko L, et al. Morphological characterization of nitrosourea-induced glioma cell lines and clones. Acta Neuropathol. 51: 23-31, 1980. PubMed: 7435138

Tzeng JJ, et al. Adoptive immunotherapy of a rat glioma using lymphokine-activated killer cells and interleukin 2. Cancer Res. 50: 4338-4343, 1990. PubMed: 2364388

Barth RF, et al. Boron Neutron capture therapy of brain tumors: Enhanced survival following intracarotid injection of either sodium borocaptate or boronophenylalanine with or without blood brain barrier disruption. Cancer Res. 57: 1129-1136, 1997. PubMed: 9067283

Clendenon NR, et al. Boron neutron capture therapy of a rat glioma. Neurosurgery 26: 47-55, 1990. PubMed: 2294479

Matalka KZ, et al. Neutron capture therapy of a rat glioma using boronophenylalanine as a capture agent. Radiat. Res. 137: 44-51, 1994. PubMed: 8265787

Tzeng JJ, et al. Phenotype and functional activity of tumor-infiltrating lymphocytes isolated from immunogenic and nonimmunogenic rat brain tumors. Cancer Res. 51: 2373-2378, 1991. PubMed: 2015600

Gyngell ML, et al. Localized proton NMR spectroscopy of experimental gliomas in rat brain in vivo. NMR Biomed. 5: 335-340, 1992. PubMed: 1336973

Bockhorst K, et al. Localization of experimental brain tumors in MRI by gadolinium porphyrin. Acta Neurochir. Suppl. (Wien) 60: 347-349, 1994. PubMed: 7976586

Els T, et al. NMR contrast enhancement of brain tumors: Comparison of the blood brain barrier tracer GdDTPA and the tumor-selective contrast agent in MnTPPS. MAGMA 1: 126-133, 1993.

Hossmann KA, et al. Regional metabolism of experimental brain tumors. Acta Neuropathol. 69: 139-147, 1986. PubMed: 3962590

Eis M, et al. High resolution quantitative relaxation and diffusion MRI of three different experimental brain tumors in rat. Magn. Reson. Med. 34: 835-844, 1995. PubMed: 8598810

Eis M, et al. Quantitative diffusion MR imaging of cerebral tumor and edema. Acta Neurochir. Suppl. (Wien) 60: 344-346, 1994. PubMed: 7976585

Judy KD, et al. Effectiveness of controlled release of a cyclophosphamide derivative with polymers against rat gliomas. J. Neurosurg. 82: 481-486, 1995. PubMed: 7861228

Ernestus RI, et al. Identification of intracranial liqor metastases of experimental stereotactically implanted brain tumors by the tumor-selective MRI contrast agent MnTPPS. Clin. Exp. Metastasis 10: 345-350, 1992. PubMed: 1505124

Yang W, et al. Boron neutron capture therapy of brain tumors: enhanced survival following intracarotid injection of sodium borocaptate with or without blood-brain barrier disruption. Int. J. Radiat. Oncol. Biol. Phys. 37: 663-672, 1997. PubMed: 9112465

Yang W, et al. Enhanced survival of glioma bearing rats following boron neutron capture therapy with blood-brain barrier disruption and intracarotid injection of boronophenylalanine. J. Neuro-Oncol. 33: 59-70, 1997. PubMed: 9151224

Boucher Y, et al. Interstitial fluid pressure in intracranial tumours in patients and in rodents. Br. J. Cancer 75: 829-836, 1997. PubMed: 9062403

Barba D, et al. Tumor immunity, immunizations and herpes simplex virus-thymidine kinase mediated tumor regression. Abstr. 1st Scientific Meeting Soc. Neuro-Onco. : 1996..

Vinores SA, Koestner A. The effect of nerve growth factor on undifferentiated glioma cells. Cancer Lett. 10: 309-318, 1980. PubMed: 7427924

Kobayashi N, et al. An improved rat brain-tumor model. J. Neurosurg. 53: 808-815, 1980. PubMed: 7003068

Barth RF. Rat brain tumor models in experimental neuro-oncology: the 9L, C6, T9, F98, RG2 (D74), RT-2 and CNS-1 gliomas. J. Neuro-Oncol. 36: 91-102, 1998. PubMed: 9525831

Basic Documentation
References

Ko L, et al. Morphological characterization of nitrosourea-induced glioma cell lines and clones. Acta Neuropathol. 51: 23-31, 1980. PubMed: 7435138

Tzeng JJ, et al. Adoptive immunotherapy of a rat glioma using lymphokine-activated killer cells and interleukin 2. Cancer Res. 50: 4338-4343, 1990. PubMed: 2364388

Barth RF, et al. Boron Neutron capture therapy of brain tumors: Enhanced survival following intracarotid injection of either sodium borocaptate or boronophenylalanine with or without blood brain barrier disruption. Cancer Res. 57: 1129-1136, 1997. PubMed: 9067283

Clendenon NR, et al. Boron neutron capture therapy of a rat glioma. Neurosurgery 26: 47-55, 1990. PubMed: 2294479

Matalka KZ, et al. Neutron capture therapy of a rat glioma using boronophenylalanine as a capture agent. Radiat. Res. 137: 44-51, 1994. PubMed: 8265787

Tzeng JJ, et al. Phenotype and functional activity of tumor-infiltrating lymphocytes isolated from immunogenic and nonimmunogenic rat brain tumors. Cancer Res. 51: 2373-2378, 1991. PubMed: 2015600

Gyngell ML, et al. Localized proton NMR spectroscopy of experimental gliomas in rat brain in vivo. NMR Biomed. 5: 335-340, 1992. PubMed: 1336973

Bockhorst K, et al. Localization of experimental brain tumors in MRI by gadolinium porphyrin. Acta Neurochir. Suppl. (Wien) 60: 347-349, 1994. PubMed: 7976586

Els T, et al. NMR contrast enhancement of brain tumors: Comparison of the blood brain barrier tracer GdDTPA and the tumor-selective contrast agent in MnTPPS. MAGMA 1: 126-133, 1993.

Hossmann KA, et al. Regional metabolism of experimental brain tumors. Acta Neuropathol. 69: 139-147, 1986. PubMed: 3962590

Eis M, et al. High resolution quantitative relaxation and diffusion MRI of three different experimental brain tumors in rat. Magn. Reson. Med. 34: 835-844, 1995. PubMed: 8598810

Eis M, et al. Quantitative diffusion MR imaging of cerebral tumor and edema. Acta Neurochir. Suppl. (Wien) 60: 344-346, 1994. PubMed: 7976585

Judy KD, et al. Effectiveness of controlled release of a cyclophosphamide derivative with polymers against rat gliomas. J. Neurosurg. 82: 481-486, 1995. PubMed: 7861228

Ernestus RI, et al. Identification of intracranial liqor metastases of experimental stereotactically implanted brain tumors by the tumor-selective MRI contrast agent MnTPPS. Clin. Exp. Metastasis 10: 345-350, 1992. PubMed: 1505124

Yang W, et al. Boron neutron capture therapy of brain tumors: enhanced survival following intracarotid injection of sodium borocaptate with or without blood-brain barrier disruption. Int. J. Radiat. Oncol. Biol. Phys. 37: 663-672, 1997. PubMed: 9112465

Yang W, et al. Enhanced survival of glioma bearing rats following boron neutron capture therapy with blood-brain barrier disruption and intracarotid injection of boronophenylalanine. J. Neuro-Oncol. 33: 59-70, 1997. PubMed: 9151224

Boucher Y, et al. Interstitial fluid pressure in intracranial tumours in patients and in rodents. Br. J. Cancer 75: 829-836, 1997. PubMed: 9062403

Barba D, et al. Tumor immunity, immunizations and herpes simplex virus-thymidine kinase mediated tumor regression. Abstr. 1st Scientific Meeting Soc. Neuro-Onco. : 1996..

Vinores SA, Koestner A. The effect of nerve growth factor on undifferentiated glioma cells. Cancer Lett. 10: 309-318, 1980. PubMed: 7427924

Kobayashi N, et al. An improved rat brain-tumor model. J. Neurosurg. 53: 808-815, 1980. PubMed: 7003068

Barth RF. Rat brain tumor models in experimental neuro-oncology: the 9L, C6, T9, F98, RG2 (D74), RT-2 and CNS-1 gliomas. J. Neuro-Oncol. 36: 91-102, 1998. PubMed: 9525831